Abstract
The aim of this study is to determine serum anti-melanoma differentiation-associated gene 5 prevalence and their clinical associations in Chinese patients with polymyositis and dermatomyositis (PM/DM). Serum anti-MDA5 antibody was detected by ELISA in 113 adult PM/DM patients and in various controls. Flow cytometry was applied to analyze the subgroups of lymphocytes in the peripheral blood of PM/DM patients. The serum anti-MDA5-positive rate in the DM patients (22.6%) was significantly higher compared with that in PM patients (0%, P < 0.005), patients with SLE (3.3%, P < 0.05), RA (3.3%, P < 0.05), pSS (0%, P < 0.05), pulmonary infection (0%, P < 0.05) and healthy controls (0%, P < 0.001). The percentage of decreased CD4+, CD8+ T cell counts, raised CD4+/CD8+ ratio in peripheral blood and the incidence of acute/subacute interstitial pneumonia (A/SIP) were significantly higher in anti-MDA5-positive DM group than negative group (all P < 0.05). Additionally, logistic multivariate analysis showed that anti-MDA5 is an independent risk factor for death of ILD in DM (OR = 8.46, 95% CI 1.77–40.36, P = 0.007). In conclusion, in Chinese PM/DM patients, serum anti-MDA5 antibody is mainly presented in DM patients and can be a useful marker for A/SIP in patients with DM. It can predict unfavorable prognosis in DM patients with ILD. Further studies are needed to identify how the abnormal T cells in peripheral blood participated in the generation of the anti-MDA5 antibody.
Similar content being viewed by others
References
Rider LG, Miller FW (2011) Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305(2):183–190
Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine LK, Danoff S, Oddis CV (2010) Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev 6(2):108–119
Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M et al (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32(9):1719–1726
Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T et al (2006) Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 28(5):1005–1012
Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S et al (2009) Clinical differences between interstitial lung diseases associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136(5):1341–1347
Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52(5):1571–1576
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of the two parts). N Engl J Med 292(7):344–347
Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine’ myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46(4):626–636
American Thoracic Society (2006) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American thoracic society (ATS), and the European respiratory society (ERS). Am J Respir Crit Care Med 161(2):646–664
Tan EM (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558
Kuwana M, Kimura K, Kawakami Y (2002) Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay. Arthritis Rheum 46(10):2742–2747
Sato S, Hoshino K, Satoh T, Suwa A, Hirakata M, Inada S et al (2008) MDA5 (melanoma-differentiation associated gene as an autoantigen recognised by anti-CADM-140 antibody in patients with clinically amyopathic dermatomyositis (abstract). Arthritis Rheum 58:S923
Sato S, Hoshino K, Satoh T, Kawakami Y, Fujita T (2009) RNA helicase encoded by melanoma differentiation—associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis. Arthritis Rheum 60(7):2193–2200
Takeuchi O, Akira S (2008) MDA5/RIG-I and virus recognition. Curr Opin Immunol 20(1):17–22
Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K et al (2008) Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205(7):1601–1610
Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T (2010) Anti-MDA5 and anti-TIF1-c antibodies have clinical significance for patients with dermatomyositis. Rheumatology 49(9):1726–1733
Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T et al (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 49(3):433–440
Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65(1):25–34
Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee E et al (2010) Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 11:223–231
Fathi M, Lundberg IE (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17(6):701–706
Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M et al (1999) Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 18(6):462–467
Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K et al (2010) Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 49(9):1713–1719
Takada T, Suzuki E, Nakano M, Kagamu H, Tsukada H, Hasegawa T et al (1998) Clinical features of polymyositis/dermatomyositis with steroid-resistant interstitial lung disease. Intern Med 37(8):669–673
Miyazaki E, Ando M, Muramatsu T, Fukami T, Matsuno O, Nureki S et al (2007) Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol 26(3):436–439
Yokoyama T, Sakamoto T, Shida N, Kinoshita M, Kunou Y, Karukaya R et al (2005) Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes. J Intens Care Med 20(3):160–163
Acknowledgments
We wish to thank professor Mimori’s laboratory for the positive control sera they kindly donated. This study was supported by The National Natural Science Foundation of China (project number: 81072457) and Beijing Municipal Science and Technology Commission-funded Project (project number: D101100050010018).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, F., Wang, D., Shu, X. et al. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 32, 3909–3915 (2012). https://doi.org/10.1007/s00296-011-2323-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-2323-y